Evidence map›Paper›PMID 26185256›Full record

ReviewStem cells translational medicine2015

Our Fat Future: Translating Adipose Stem Cell Therapy.

Rachel C Nordberg, Elizabeth G Loboa

Abstract readReview
In one paragraph

Review in Stem cells translational medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Application of adipose-derived mesenchymal stem cells in anFrontiers in cellular neuroscience · 2022
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Adipose Stem Cell Translational Applications: From Bench-to-Bedside.International journal of molecular sciences · 2018
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Rachel C NordbergJoint Department of Biomedical Engineering, North Carolina State University, Raleigh, and University of North Carolina Chapel Hill, Chapel Hill, North Carolina, USA; Department of Materials Science and Engineering, North Carolina State University, Raleigh, North Carolina, USA.
Elizabeth G LoboaJoint Department of Biomedical Engineering, North Carolina State University, Raleigh, and University of North Carolina Chapel Hill, Chapel Hill, North Carolina, USA; Department of Materials Science and Engineering, North Carolina State University, Raleigh, North Carolina, USA egloboa@ncsu.edu.

Funding

PHS HHS 550KR61325PHS HHS 550KR71418
6 · The paper itself

Abstract

unlabelledHuman adipose stem cells (hASCs) have the potential to treat patients with a variety of clinical conditions. Recent advancements in translational research, regulatory policy, and industry have positioned hASCs on the threshold of clinical translation. We discuss the progress and challenges of bringing adipose stem cell therapy into mainstream clinical use. SIGNIFICANCE: This article details the advances made in recent years that have helped move human adipose stem cell therapy toward mainstream clinical use from a translational research, regulatory policy, and industrial standpoint. Four recurrent themes in translational technology as they pertain to human adipose stem cells are discussed: automated closed-system operations, biosensors and real-time monitoring, biomimetics, and rapid manufacturing. In light of recent FDA guidance documents, regulatory concerns about adipose stem cell therapy are discussed. Finally, an update is provided on the current state of clinical trials and the emerging industry that uses human adipose stem cells. This article is expected to stimulate future studies in translational adipose stem cell research.

Indexed as

AdipocytesAdipose TissueAutomation, LaboratoryBiomimetic MaterialsBiosensing TechniquesCell- and Tissue-Based TherapyCell DifferentiationClinical Trials as TopicHumansStem CellsStem Cell TransplantationTranslational Research, BiomedicalUnited StatesUnited States Food and Drug AdministrationWorkforce

Identifiers

PMID26185256
PMCPMC4542878

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.